<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-134 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-134</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-134</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <p><strong>Paper ID:</strong> paper-f864d95e5571a5768398095c0b6ae7f015ede490</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/f864d95e5571a5768398095c0b6ae7f015ede490" target="_blank">627 Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade</a></p>
                <p><strong>Paper Venue:</strong> Journal of Investigative Dermatology</p>
                <p><strong>Cost:</strong> 0.004</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e134.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e134.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PAI-1 inhibition + ICB</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Inhibition of plasminogen activator inhibitor-1 (PAI-1) combined with immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Preclinical combination strategy in which pharmacologic or genetic inhibition of PAI-1 is combined with immune checkpoint blockade; inhibition of PAI-1 blocks PD-L1 endocytosis and is reported to improve the response of melanoma cells to checkpoint inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>627 Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor / immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>PAI-1-mediated PD-L1 endocytosis / altered PD-L1 trafficking</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>PAI-1 inhibitor + immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>PAI-1 inhibitor (unspecified) + immune checkpoint blockade agent(s) (unspecified)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Blocking PAI-1 prevents PD-L1 endocytosis, altering PD-L1 trafficking and thereby enhancing the effectiveness of immune checkpoint blockade against melanoma cells.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>preclinical (melanoma cell models)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>melanoma cell lines / melanoma cells (preclinical models); no patient cohort reported in provided text</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': '627 Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade', 'publication_date_yy_mm': '2022-08'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <p class="empty-note">No potentially relevant new papers extracted.</p>
        </div>

        </div>

    </div>
</body>
</html>